Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Western University · Probity Medical Research · +4 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
1,346
total citations
- FWCI
- 30.61
- Percentile
- 100%
- References
- 20
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Ustekinumab
- Medicine
- Psoriasis
- Psoriasis Area and Severity Index
- Placebo
- Clinical endpoint
- Dosing
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.